Advanced glycation end products in patients with cerebral infarction

Internal Medicine

Volumn 48, Issue 8, 2009, Pages 587-591

  Ohnuki, Yuko ^a   Nagano, Reiko ^a   Takizawa, Shunya ^a   Takagi, Shigeharu ^a   Miyata, Toshio ^b  

^a TOKAI UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^b TOHOKU UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

Advanced glycation end products; AGE reader; Cerebral infarction; Oxidative stress

Indexed keywords

ADVANCED GLYCATION END PRODUCT; ANGIOTENSIN RECEPTOR ANTAGONIST; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; BIOLOGICAL MARKER;

AGED; ARTICLE; AUTOFLUORESCENCE; BRAIN INFARCTION; CHRONIC DISEASE; CONTROLLED STUDY; DRUG MECHANISM; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; NON INVASIVE MEASUREMENT; OXIDATIVE STRESS; PROTEIN SYNTHESIS; SKIN; CASE CONTROL STUDY; DRUG EFFECT; METABOLISM; MIDDLE AGED; PATHOPHYSIOLOGY; PHYSIOLOGY; PREDICTION AND FORECASTING;

AGED; AGED, 80 AND OVER; ANGIOTENSIN II TYPE 1 RECEPTOR BLOCKERS; BIOLOGICAL MARKERS; CASE-CONTROL STUDIES; CEREBRAL INFARCTION; FEMALE; GLYCOSYLATION END PRODUCTS, ADVANCED; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; MALE; MIDDLE AGED; OXIDATIVE STRESS; PREDICTIVE VALUE OF TESTS; SKIN;

EID: 67649696996     PISSN: 09182918     EISSN: 13497235     Source Type: Journal    
DOI: 10.2169/internalmedicine.48.1390     Document Type: Article

References (18)

1. Mulder DJ, van Haelst PL, Gross S, et al. Skin autofluorescence is elevated in patients with stable coronary artery disease and is associated with serum levels of neopterin and the soluble receptor for advanced glycation end products. Atherosclerosis 197: 217-223, 2008.
2. Meerwaldt R, Hartog JWL, Graaff R, et al. Skin autofluorescence, a measure of cumulative metabolic stress and advanced glycation end products, predicts mortality in hemodialysis patients. J Am See Nephrol 16: 3687-3693, 2005.
3. Meerwaldt R, Graaff R, Oomen PHN, et al. Simple non-invasive assessment of advanced glycation endproduct accumulation. Diabetologia 47: 1324-1330, 2004.
4. Yan S, Ramasamy R, Naka Y, Schmidt A. Glycation, inflammation and RAGE: a scaffold for the macrovascular complications of diabetes and beyond. Circ Res 93: 1159-1169, 2003.
5. Baynes JW, Thorpe SR. Glycoxidation and lipoxidation in atherogenesis. Free Radio Biol Med 28: 1708-1716, 2000.
6. Bucciarelli LG, Kaneko M, Ananthakrishnan R, et al. Receptor for advanced-glycation end products: key modulator of myocardial ischemic injury. Circulation 113: 1226-1234, 2006.
7. Zimmerman GA, Meistrell M, Bloom O, et al. Neurotoxicity of advanced glycation end products during focal stroke and neuro-protective effects of aminoguanidine. Proc Natl Acad Sci USA 92: 3744-3748, 1995.
8. Special report from the National Institute of Neurological Disorders and Stroke. Classification of Cerebrovascular Diseases. Stroke 21: 637-676, 1990.
9. Kobayashi S, Okada K, Koide H, Bokura H, Yamaguchi S. Subcortical silent brain infarction as a risk factor for clinical stroke. Stroke 28: 1932-1939, 1997.
10. Bernick C, Kuller L, Dulberg C, et al. Cardiovascular Health Study Collaborative Research Group: Silent MRI infarcts and the risk of future stroke: the cardiovascular health study. Neurology 57: 1222-1229, 2001.
11. Verneer SE, Hollander M, van Dijk EJ, Hofman A, Koudstaal PJ, Breteler MMB. Silent brain infarcts and white matter lesions increase stroke risk in the general population: the Rotterdam Scan Study. Stroke 34: 1126-1129, 2003.
12. Tousoulis D, Zisimos K, Antoniades C, et al. Oxidative stress and inflammatory process in patients with atrial fibrillation: the role of left atrium distension. Int J Cardiol. 2008.
13. Van Wagoner DR. Oxidative stress and inflammation in atrial fibrillation: role in pathogenesis and potential as a therapeutic target. J Cardiovasc Pharmacol. 2008.
14. Matsumoto T, Tsurumoto T, Baba H, et al. Measurement of advanced glycation endproducts in skin of patients with rheumatoid arthritis, osteoarthritis, and dialysis-related spondyloarthropathy using non-invasive methods. Rheumatol Int 28: 157-160, 2007.
15. Ueno H, Koyama H, Tanaka S, et al. Skin autofluorescence, a marker for advanced glycation end product accumulation, is associated with arterial stiffness in patients with end-stage renal disease. Metabolism 58: 1452-1457, 2008.
16. Miyata T, Izuhara Y. Inhibition of advanced glycation end products: an implicit goal in clinical medicine for the treatment of diabetic nephropathy? Ann NY Acad Sci 1126: 141-146, 2008.
17. Jinnouchi Y, Yamagishi S, Takeuchi M, et al. Atorvastatin decreases serum levels of advanced glycation end products (AGEs) in patients with type 2 diabetes. Clin Exp Med 6: 191-193, 2006.
18. Hankey GJ. Potential new risk factors for ischemic stroke: What is their potential? Stroke 37: 2181-2188, 2006.